BEDFORD, Mass., June 18, 2015 /PRNewswire/ -- Hologic, Inc. (NASDAQ: HOLX) announced today that it has launched, subject to market and other conditions, a private offering of $1.0 billion aggregate principal amount of its senior notes due 2022. Hologic intends to use the proceeds of the offering, plus available cash, to redeem its outstanding 6.25% senior notes due 2020 in the aggregate principal amount of $1.0 billion.
The 2022 notes will not be registered under the Securities Act of 1933, as amended, or any state securities laws. Unless so registered, the securities may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. The 2022 notes are being offered only to qualified institutional buyers in reliance on Rule 144A under the Securities Act, and outside the United States in accordance with Regulation S under the Securities Act.
Hologic will redeem the 2020 notes on August 1, 2015, subject to the completion of the offering and the receipt of its proceeds, for an aggregate redemption price of $1.03125 billion. In addition, Hologic will make a final interest payment in the amount of $31.25 million for interest accrued to August 1, 2015, to holders of record of the 2020 notes as of July 15, 2015.
This press release is neither an offer to sell nor a solicitation of an offer to buy any of these securities, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction where the offer, solicitation or sale is not permitted. This press release shall not constitute a notice of redemption with respect to the 6.25% senior notes due 2020.
This press release contains forward-looking information that involves risks and uncertainties, including statements about the Company's plans, objectives, expectations and intentions. Such statements include, without limitation, the Company's intention to issue the 2022 notes in a private placement pursuant to Rule 144A under the Securities Act of 1933, and outside the United States in accordance with Regulation S under the Securities Act, and to redeem the 2020 notes using the proceeds of the offering. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. The offering and/or the redemption may also be adversely affected by prevailing credit markets, which have been subject to significant volatility, or adverse changes to Hologic's business or prospects. Hologic cannot assure it will complete the issuance of the 2022 notes, or the redemption, on favorable terms, if at all. The risks included above are not exhaustive. Other factors that could adversely affect the Company's business and prospects are described in the filings made by Hologic with the SEC. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
Vice President, Investor Relations and
SOURCE Hologic, Inc.